PTKFY:OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
8,50 US$
0,00%
(0,00) 1D
12. okt., 10.22.09 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for PTKFY...
Markedsværdi
36,51 bio.
Gns. vol.
1,96 t
Volumen
69,00
Højeste i 52 uger
16,36 US$
Laveste i 52 uger
7,63 US$
Beta
0,09
Aktier i omløb
234,07 mio.
Antal ansatte
13 t
Markedsværdi
36,51 bio.
Gns. vol.
1,96 t
Volumen
69,00
Højeste i 52 uger
16,36 US$
Laveste i 52 uger
7,63 US$
Beta
0,09
Aktier i omløb
234,07 mio.
Antal ansatte
13 t
Nyhedshistorier
Fra webkilder og nyhedspartnere
ad-hoc-news.de
·
for 7 timer siden
Kalbe Farma launched an IDR 500 billion buyback of Kalbe Farma stock
ad-hoc-news.de
·
for 1 dag siden
Kalbe Farma announced IDR 500 billion buyback of Kalbe Farma stock
ad-hoc-news.de
·
for 2 dage siden
Kalbe Farma stock at EUR 0.04 with IDR 34.6 trillion market cap
ad-hoc-news.de
·
for 2 dage siden
UBS keeps IDR 1,100 target for Kalbe Farma stock
Profil
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Om PT Kalbe Farma Unsponsored Indonesia ADR